title: Current approaches to novel therapeutics in pancreatic cancer.
abstract: Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.
authors.affiliation: Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA.
authors.forename: Corina E
authors.initials: CE
authors.lastname: Akerele
authors.forename: Irina
authors.initials: I
authors.lastname: Rybalova
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
authors.forename: Sridhar
authors.initials: S
authors.lastname: Mani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant
chemical_list: D000970:Antineoplastic Agents